配合化学療法市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、投与経路別、がんタイプ別、流通チャネル別、地域別、競合別セグメント、2020-2030F

配合化学療法の世界市場規模は2024年に50億7,000万米ドルとなり、予測期間では2030年までCAGR 5.08%で目覚ましい成長が見込まれています。

配合化学療法は、がん患者の個々のニーズに合わせてカスタマイズされた化学療法薬を調製する専門的な業務を指します。このプロセスは、必要な専門知識、設備、インフラを備えた調剤薬局またはヘルスケア施設によって実施されます。配合された化学療法薬は、内服液、カプセル、外用クリーム、坐剤、静脈内投与製剤など、さまざまな剤形で調製されます。どの剤形を選択するかは、患者の医療上の必要性、嗜好、治療計画の具体的要件によって決まる。配合化学療法は、特に小児および老年期の患者にとって有用です。小児および老年期の患者は、独特な投薬が必要であったり、従来の錠剤やカプセルを嚥下することが困難であったりします。配合剤は、これらの患者の特定のニーズを満たすように設計することができます。

市場促進要因

医薬品開発の進歩

主な市場課題

品質管理と安全性

主な市場動向

無菌調合への関心の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の配合化学療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤の種類別（細胞傷害性薬剤、ホルモン剤、免疫調節剤、標的療法、支持療法薬）
  • 投与経路別（静脈内、経口、皮下、筋肉内、髄腔内）
  • がんの種類別（乳がん、肺がん、大腸がん、前立腺がん、白血病、リンパ腫、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の配合化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の配合化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の配合化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の配合化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの配合化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer S.P.A.
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline S.R.L.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Compounding Chemotherapy Market was valued at USD 5.07 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.08% through 2030. Compounding chemotherapy refers to the specialized practice of preparing customized chemotherapy medications tailored to the individual needs of cancer patients. This process is carried out by compounding pharmacies or healthcare facilities with the necessary expertise, equipment, and infrastructure. Compounded chemotherapy medications can be prepared in various dosage forms, such as oral solutions, capsules, topical creams, suppositories, and intravenous (IV) formulations. The choice of dosage form depends on the patient's medical needs, preferences, and the specific requirements of the treatment plan. Compounding chemotherapy is particularly valuable for pediatric and geriatric patients who may have unique dosing requirements or difficulty swallowing conventional pills or capsules. Compounded formulations can be designed to meet the specific needs of these populations.

Key Market Drivers

Advancements in Drug Development

Targeted therapies have revolutionized cancer treatment by specifically targeting molecules or pathways involved in cancer growth. These therapies are designed to be more selective in attacking cancer cells while sparing healthy ones. Compounded chemotherapy drugs now include a range of targeted agents tailored to individual patient profiles. Immunotherapy drugs, such as immune checkpoint inhibitors, have emerged as a promising approach to cancer treatment. These drugs harness the patient's immune system to recognize and attack cancer cells. Compounding pharmacies prepare these immunotherapies for administration, contributing to their widespread use. The development and approval of biosimilar versions of some chemotherapy agents have increased access to these treatments while reducing costs. Compounding pharmacies may be involved in preparing and supplying biosimilars, ensuring their availability. Nanoparticle-based chemotherapy formulations have been developed to improve drug delivery and enhance the therapeutic index of chemotherapy agents. These nanocarriers can target cancer cells more precisely and reduce side effects. Compounding pharmacies are involved in preparing these advanced formulations. Liposomal encapsulation is a drug delivery technique that involves enclosing chemotherapy drugs in liposomes (tiny fat bubbles). This approach improves drug solubility, extends drug circulation in the body, and enhances drug delivery to tumor sites. Compounded liposomal chemotherapy formulations are increasingly used. Ongoing research efforts continue to identify new chemotherapy agents, combination therapies, and treatment regimens. Compounding pharmacies play a pivotal role in preparing and supplying these innovative drugs for clinical use and research purposes.

Key Market Challenges

Quality Control and Safety

Compounded medications, including chemotherapy drugs, must adhere to strict regulatory guidelines and standards set by government agencies like the U.S. Food and Drug Administration (FDA) in the United States. Compliance with these regulations is critical to ensure the safety and efficacy of compounded drugs. Maintaining consistent quality in compounded chemotherapy drugs is challenging due to variations in raw materials, compounding processes, and equipment. Quality control measures must be in place to ensure that each batch of compounded medication meets established standards. Chemotherapy drugs are typically administered intravenously, which necessitates strict sterility measures during compounding. Contamination can lead to severe infections and adverse patient outcomes. Maintaining sterility is a constant concern. Cross-contamination is a risk when multiple chemotherapy drugs are compounded in the same facility. Stringent cleaning and sanitation procedures are essential to prevent unintended mixing of drugs and contamination. Precise dosing is critical in chemotherapy to achieve the desired therapeutic effect while minimizing side effects. Variability in dosing can lead to treatment failures or toxicity. Ensuring the accuracy of compounded doses is challenging but essential. Some chemotherapy drugs are chemically unstable and can degrade over time. Compounding pharmacies must monitor and manage drug stability to ensure that patients receive medications with the intended potency and efficacy.

Key Market Trends

Rising Interest in Sterile Compounding

Sterile compounding is essential for chemotherapy drugs, which are often administered intravenously or directly into the bloodstream. Ensuring sterility prevents the risk of infections and other complications, which can be life-threatening for cancer patients with compromised immune systems. Many chemotherapy drugs are potent and require precise dosing and administration. Sterile compounding allows for the accurate preparation of these drugs to minimize the risk of dosage errors. Sterile compounding facilitates the customization of chemotherapy regimens based on individual patient profiles, including cancer type, stage, and medical history. This personalized approach aligns with the trend toward precision medicine. The development of advanced drug delivery methods, such as nanoparticle-based formulations and liposomal encapsulation, has increased the demand for sterile compounding. These delivery systems require aseptic preparation. The focus on patient-centered care in oncology emphasizes providing treatments that are safe, effective, and tailored to individual patient needs. Sterile compounding supports this approach by ensuring the highest standards of safety and quality.

Key Market Players

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer S.P.A.
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline S.R.L

Report Scope:

In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounding Chemotherapy Market, By Drug Type:

• Cytotoxic Drugs
• Hormonal Agents
• Immunomodulatory Agents
• Targeted Therapies
• Supportive Care Drugs

Compounding Chemotherapy Market, By Route of Administration:

• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• Intrathecal

Compounding Chemotherapy Market, By Cancer Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma

Compounding Chemotherapy Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Compounding Chemotherapy Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.

Available Customizations:

Global Compounding Chemotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Compounding Chemotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs)
  • 5.2.2. By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
  • 5.2.3. By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Compounding Chemotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Cancer Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Compounding Chemotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Mexico Compounding Chemotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Canada Compounding Chemotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Compounding Chemotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Cancer Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Compounding Chemotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Compounding Chemotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Compounding Chemotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Compounding Chemotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Compounding Chemotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Compounding Chemotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Cancer Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Compounding Chemotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Compounding Chemotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. South Korea Compounding Chemotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Japan Compounding Chemotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Cancer Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Compounding Chemotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Cancer Type
      • 8.3.5.2.4. By Distribution Channel

9. South America Compounding Chemotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Cancer Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Compounding Chemotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Compounding Chemotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Compounding Chemotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Compounding Chemotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Cancer Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Compounding Chemotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Compounding Chemotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Compounding Chemotherapy market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Baxter International Inc.
  • 15.2.1. Business Overview
  • 15.2.2. Company Snapshot
  • 15.2.3. Products & Services
  • 15.2.4. Financials (In case of listed companies)
  • 15.2.5. Recent Developments
  • 15.2.6. SWOT Analysis
• 15.3. Grifols SA
  • 15.3.1. Business Overview
  • 15.3.2. Company Snapshot
  • 15.3.3. Products & Services
  • 15.3.4. Financials (In case of listed companies)
  • 15.3.5. Recent Developments
  • 15.3.6. SWOT Analysis
• 15.4. Comecer S.P.A.
  • 15.4.1. Business Overview
  • 15.4.2. Company Snapshot
  • 15.4.3. Products & Services
  • 15.4.4. Financials (In case of listed companies)
  • 15.4.5. Recent Developments
  • 15.4.6. SWOT Analysis
• 15.5. Arxium Inc.
  • 15.5.1. Business Overview
  • 15.5.2. Company Snapshot
  • 15.5.3. Products & Services
  • 15.5.4. Financials (In case of listed companies)
  • 15.5.5. Recent Developments
  • 15.5.6. SWOT Analysis
• 15.6. Dedalus Group
  • 15.6.1. Business Overview
  • 15.6.2. Company Snapshot
  • 15.6.3. Products & Services
  • 15.6.4. Financials (In case of listed companies)
  • 15.6.5. Recent Developments
  • 15.6.6. SWOT Analysis
• 15.7. B. Braun Melsungen AG
  • 15.7.1. Business Overview
  • 15.7.2. Company Snapshot
  • 15.7.3. Products & Services
  • 15.7.4. Financials (In case of listed companies)
  • 15.7.5. Recent Developments
  • 15.7.6. SWOT Analysis
• 15.8. Omnicell Technologies Inc.
  • 15.8.1. Business Overview
  • 15.8.2. Company Snapshot
  • 15.8.3. Products & Services
  • 15.8.4. Financials (In case of listed companies)
  • 15.8.5. Recent Developments
  • 15.8.6. SWOT Analysis
• 15.9. The Metrix Company
  • 15.9.1. Business Overview
  • 15.9.2. Company Snapshot
  • 15.9.3. Products & Services
  • 15.9.4. Financials (In case of listed companies)
  • 15.9.5. Recent Developments
  • 15.9.6. SWOT Analysis
• 15.10.Sterline S.R.L.
  • 15.10.1. Business Overview
  • 15.10.2. Company Snapshot
  • 15.10.3. Products & Services
  • 15.10.4. Financials (In case of listed companies)
  • 15.10.5. Recent Developments
  • 15.10.6. SWOT Analysis

16. Strategic Recommendations

17. About Us & Disclaimer